All-trans retinoic acid and anthracycline monochemotherapy for the treatment of elderly patients with acute promyelocytic leukemia

Blood

Volumn 104, Issue 12, 2004, Pages 3490-3493

  Sanz, Miguel A ^a   Vellenga, Edo ^b   Rayón, Chelo ^b   Díaz Mediavilla, Joaquín ^b   Rivas, Concha ^b   Amutio, Elena ^b   Arias, Jesús ^b   Debén, Guillermo ^b   Novo, Andrés ^b   Bergua, Juan ^b   De La Serna, Javier ^b   Bueno, Javier ^b   Negri, Silvia ^b   Beltrán De Heredia, José M ^b   Martín, Guillermo ^b  

^a HOSPITAL UNIVERSITARIO LA FE   (Spain)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; IDARUBICIN; MERCAPTOPURINE; METHOTREXATE; MITOXANTRONE; RETINOIC ACID;

ADULT; AGE; AGED; ARTICLE; CANCER RECURRENCE; CANCER SURVIVAL; CLINICAL TRIAL; DEATH; DRUG EFFICACY; FEMALE; HIGH RISK PATIENT; HUMAN; INCIDENCE; LEUKEMIA REMISSION; LOW DRUG DOSE; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MULTICENTER STUDY; PATIENT COMPLIANCE; PRIORITY JOURNAL; PROMYELOCYTIC LEUKEMIA; SIDE EFFECT; TREATMENT OUTCOME;

EID: 9444297295     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood-2004-04-1642     Document Type: Article

References (12)

1. Mandelli F, Diverio D, Avvisati G, et al. Molecular remission in PML/RARα-positive acute promyelocytic leukemia by combined all-trans retinoic acid and idarubioin (AIDA) therapy. Blood. 1997;90: 1014-1021.
2. Mandelli F, Latagliata R, Avvisati G, et al. Treatment of elderly patients (≥ 60 years) with newly diagnosed acute promyelocytic leukaemia. Results of the Italian multicenter group GIMEMA with ATRA and idarubicin (AIDA) protocols. Leukemia. 2003;17:1085-1090.
3. Fenaux P, Chastang C, Sanz MA, et al. A randomized comparison of ATRA followed by chemotherapy and ATRA plus chemotherapy, and the rote of maintenance therapy in newly diagnosed acute promyelocytic leukemia. Blood. 1999;94:1192-1200.
4. Bumett AK, Grimwade D, Solomon E, Wheatley K, Goldstone AH, on behalf of the MRC Adult Leukemia Working Party. Presenting white blood cell count and kinetics of molecular remission predict prognosis in acute promyelocytic leukemia treated with all-trans retinoic acid: result of the randomized MRC trial. Blood. 1999;93:4131-4143.
5. Sanz MA, Martín G, Rayón C, et al. A modified AIDA protocol with anthracycline-based consolidation results in high antileukemic efficacy and reduced toxicity in newly diagnosed PML/RARα-positive acute promyelocytic leukemia. Blood. 1999;94:3015-3021.
6. Sanz MA, Martín G, González M, et al. Risk-adapted treatment of acute promyelocytic leukemia with all-trans retinoic acid and anthracycline monochemotherapy: a multicenter study by the PETHEMA Group. Blood. 2004;103:1237-1243.
7. Sanz MA, Lo Coco F, Martín G, et al. Definition of relapse risk and role of non-anthracycline drugs for consolidation in patients with acute promyelocytic leukemia: a joint study of the PETHEMA and GIMEMA cooperative groups. Blood. 2000;96: 1247-1253.
8. Cheson BD, Bennett JM, Kopecky K, et al. Revised Recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. J Clin Oncol. 2003;21:4642-4649.
9. Kaplan EL, Meier P. Nonparametric estimations from incomplete observations. J Am Stat Assoc. 1958;53:457-481.
10. Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep. 1966;50:163-170.
11. Gray RJ. A class of K-sample test for comparing the cumulative incidence of a competing risk. Ann Stat. 1988;16:1141-1154.
12. Pepe MS, Mori M. Kaplan-Meier, marginal or conditional probability curves in summarizing competing risk failure time data? Stat Med. 1993;12:737-751.